title: Combination treatment with ribavirin and interferon for coxsackievirus B3 replication.
abstract: The effects of combined treatment with ribavirin and recombinant human leukocyte interferon-alpha A/D against Coxsackievirus B3 replication were investigated in cultured cells. Recombinant human leukocyte interferon-alpha A/D was applied 12 hours before Coxsackievirus B3 inoculation and ribavirin was applied 1 hour after Coxsackievirus B3 inoculation on FL (human amnion) cell monolayers. These drugs inhibited Coxsackievirus B3 replication synergistically by plaque-reduction assay. This method of applying drugs may be useful in preventing and treating Coxsackie B virus infection.
authors.affiliation: Department of Internal Medicine, Faculty of Medicine, Kyoto University, Japan.
authors.forename: I
authors.initials: I
authors.lastname: Okada
authors.forename: A
authors.initials: A
authors.lastname: Matsumori
authors.forename: Y
authors.initials: Y
authors.lastname: Matoba
authors.forename: M
authors.initials: M
authors.lastname: Tominaga
authors.forename: T
authors.initials: T
authors.lastname: Yamada
authors.forename: C
authors.initials: C
authors.lastname: Kawai
mesh_terms: D002460:Cell Line; D004357:Drug Synergism; D029822:Enterovirus B, Human / Q000187:drug effects* / Q000502:physiology*; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage / Q000494:pharmacology*; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage / Q000494:pharmacology*; D014779:Virus Replication / Q000187:drug effects*
chemical_list: D007370:Interferon Type I; D011994:Recombinant Proteins; D012254:Ribavirin